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Abstract
The P2Y1 receptor is a membrane-bound G protein-coupled receptor stimulated by adenine
nucleotides. Using alanine scanning mutagenesis, the role in receptor activation of charged amino
acids (Asp, Glu, Lys, and Arg) and cysteines in the extracellular loops (EL) of the human P2Y1
receptor has been investigated. The mutant receptors were expressed in COS-7 cells and measured
for stimulation of phospholipase C induced by the potent agonist 2-methylthioadenosine-5′-
diphosphate (2-MeSADP). In addition to single point mutations, all receptors carried the
hemagglutinin epitope at the N-terminus for detection of cell-surface expression. The C124A and
C202A mutations, located near the exofacial end of transmembrane helix 3 and in EL2,
respectively, ablated phospholipase C stimulation by ≤100 μM 2-MeSADP. Surface enzyme-
linked immunosorbent assay detection of both mutant receptors showed <10% expression,
suggesting that a critical disulfide bridge between EL2 and the upper part of transmembrane 3, as
found in many other G protein-coupled receptors, is required for proper trafficking of the P2Y1
receptor to the cell surface. In contrast, the C42A and C296A mutant receptors (located in the N-
terminal domain and EL3) were activated by 2-MeSADP, but the EC50 values were >1000-fold
greater than for the wild-type receptor. The double mutant receptor C42A/C296A exhibited no
additive shift in the concentration-response curve for 2-MeSADP. These data suggest that Cys42
and Cys296 form another disulfide bridge in the extracellular region, which is critical for
activation. Replacement of charged amino acids produced only minor changes in receptor
activation, with two remarkable exceptions. The E209A mutant receptor (EL2) exhibited a >1000-
fold shift in EC50. However, if Glu209 were substituted with amino acids capable of hydrogen
bonding (Asp, Gln, or Arg), the mutant receptors responded like the wild-type receptor. Arg287 in
EL3 was impaired similarly to Glu209 when substituted by alanine. Substitution of Arg287 by
lysine, another positively charged residue, failed to fully restore wild-type activity.
P2 receptors have been divided into two structurally distinct families as follows: the P2X
receptor class of ligand-gated ion channels, which are primarily activated by ATP, and the
P2Y receptor class of G protein-coupled receptors (GPCRs),1 which are activated by both
extracellular adenine and uridine nucleotides (1–3). As many as 11 subtypes of P2Y
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receptors have been cloned, but only 5 of these are from mammalian species and have been
shown to be functionally activated by extracellular nucleotides. Of these 11, several may be
either non-nucleotide receptors such as P2Y5, P2Y7, P2Y9, and P2Y10 or species
homologues like p2y3 and P2Y6. The P2Y1 subtype specifically recognizes adenine
nucleotides, which act as either potent agonists (e.g. 2-methylthio-ADP) or selective
antagonists (e.g. MRS 2179). The P2Y1 receptor, which is coupled to activation of
phospholipase C (PLC), is expressed in heart muscle, skeletal muscle, and various smooth
muscle cells and is associated with the vasodilatory action of ATP (3). In platelets, it serves
as one of the receptors through which ADP induces aggregation, an action attenuated by
ATP and other triphosphate derivatives (4).
Previously we have investigated the determinants of ligand recognition in P2Y1 receptors
using site-directed mutagenesis of specific amino acid residues in the transmembrane helical
domains (TMs) (5), molecular modeling based on similarity to rhodopsin in sequence and
overall geometry (6), and the chemical synthesis of novel agonists (7) and antagonists (8).
Positively charged and other conserved residues in TM3, TM6, and TM7, such as Arg128,
Arg310, and Ser314, were found to be critical for the activation by nucleotides of human
P2Y1 receptors. A molecular model of the TM domains based on these findings has been
proposed (6).
Most of the interest in GPCRs to date has focused on the TM domains for locating amino
acids that are specifically involved in recognition of small, non-peptide ligands, including
nucleotides (5, 9, 10). However, for peptide receptors residues within the extracellular loops
(ELs) are essential for ligand recognition (11). Currently, there is accumulating evidence
that residues within the ELs are also important in GPCRs that recognize small molecules as
ligands. In adenosine receptors, amino acids in EL2 were shown to be involved in agonist
and antagonist binding (12) and high affinity binding of xanthine antagonists (13). In the
thyrotropin-releasing hormone receptor, amino acids in EL2 and EL3 were found to be
important for ligand binding (14). In the α1-adrenergic receptor, three amino acids at the C-
terminal end of EL2 were shown to be responsible for subtype-specific antagonist binding
(15). In angiotensin II type 2 receptors, amino acid residues in EL2 and EL3 contribute to
angiotensin II binding (16), whereas in angiotensin II type 1 receptors, an additional residue
in EL1 is involved in this process (17).
A conserved disulfide bridge between Cys residues in the second extracellular loop (EL2)
and the exofacial end of TM3 has been shown to be essential for various biogenic amine and
other GPCRs. It is generally thought that this disulfide bond is required to maintain overall
receptor geometry, although its role in transport to the cell surface is contradictory (18, 19).
An additional disulfide bridge between a cysteine in the EL3 and the N-terminal domain was
found in the angiotensin receptor (20). The extracellular portions of the human P2Y1
receptor carry four cysteines, and sequence comparison has revealed that all of these
cysteines are conserved among P2Y receptors (21). Hence P2Y receptors might form two
disulfide bridges within the extracellular receptor portions.
Interestingly, the P2Y receptors are GPCRs that recognize small molecules as ligands, but
they exhibit the highest sequence identity with peptide receptors such as somatostatin,
platelet-activating factor, angiotensin II, and neuropeptide Y receptors (22). Because of this
paradox (binding of a small ligand and sequence homology with peptide receptors), we have
investigated the role of amino acids in the ELs in human P2Y1 receptor activation.
The aim of this study was to identify amino acids that potentially may be involved in either
direct ligand contact or in conformational restriction of the ELs. We hypothesized that
disruption of either of the two potential disulfide bonds in the ELs or substitution of amino
Hoffmann et al. Page 2













acids potentially involved in ionic interactions (Asp, Glu, Lys, or Arg) might have a marked
effect on ligand recognition and thus receptor-mediated activation of PLC.
EXPERIMENTAL PROCEDURES
Materials
The expression construct coding for the human P2Y1 receptor (pCDP2Y1) was prepared as
described previously (5). Vent DNA polymerase and all endonuclease restriction enzymes
used in this study were obtained from New England Biolabs (Beverly, MA). The agonists 2-
MeSATP and 2-MeSADP were from Research Biochemicals (Natick, MA). The agonist 2-
hexylthioadenosine-5′-monophosphate (HT-AMP) was synthesized as described (7, 23) as
the ammonium salt, which was more soluble in aqueous medium than the triethylammonium
salt. myo-[3H]Inositol (15 Ci/mmol) was obtained from American Radiolabeled Chemicals.
Fetal bovine serum (FBS) was from Life Technologies, Inc. o-Phenylenediamine
dihydrochloride was purchased from Sigma. The Sequenase Kit version 2.0 was from
Amersham Pharmacia Biotech. All oligonucleotides were synthesized by Bioserve
Biotechnologies (Laurel, MD). A monoclonal antibody (12CA5) against a hemagglutinin
epitope (HA) was purchased from Roche Molecular Biochemicals, and goat anti-mouse IgG
(γ-chain-specific) antibody conjugated with horseradish peroxidase was purchased from
Sigma. DEAE-dextran was obtained from Amersham Pharmacia Biotech.
Plasmid Construction and Site-directed Mutagenesis
All mutations were introduced into pCDP2Y1 (5) using standard polymerase chain reaction
mutagenesis techniques (24). The accuracy of all polymerase chain reaction-derived
sequences was confirmed by dideoxy sequencing of the mutant plasmids (25).
Epitope Tagging
As described previously (5) a 9-amino acid sequence derived from the influenza virus
hemagglutinin (HA) protein (TAC CCA TAC GAC GTG CCA GAC TAC GCG; peptide
sequence: YPYDVPDYA) was inserted after the initiating methionine residue in the
extracellular N terminus of the human P2Y1 receptor gene. A hexahistidine tag (26) was also
included at the C terminus immediately after the ultimate leucine residue resulting in a
construct suitable for potential affinity chromatography using a nickel column.
Transient Expression of Mutant Receptors in COS-7 Cells
4 × 106 COS-7 cells were seeded into 150-mm culture dishes containing 25 ml of
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 100 units/ml
penicillin, 100 μg/ml streptomycin, and 2 μmol/ml glutamine. Cells were transfected
approximately 24 h later with plasmid DNA (10 μg DNA/dish) using the DEAE-dextran
method (27) for 40 min, followed by treatment with 100 μM chloroquine for 2.5 h, and
grown for an additional 24 h at 37 °C and 5% CO2.
Inositol Phosphate Determination
Assays were carried out according to the general approach of Harden et al. (28). About 24 h
after transfection, the cells were split into 6-well plates (Costar, ~0.75 × 106 cells/well) in
DMEM culture medium supplemented with 3 μCi/ml myo-[3H]inositol. After a 24-h
labeling period, cells were preincubated with 10 mM LiCl for 20 min at room temperature.
The mixtures were slightly swirled to ensure uniformity. Following the addition of agonists,
the cells were incubated for 30 min at 37 °C, 5% CO2. The supernatant was removed by
aspiration, and 750 μl of cold 20 mM formic acid was added to each well. After a 30-min
incubation at 4 °C, cell extracts were neutralized with 250 μl of 60 mM NH4OH. The
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inositol monophosphate fraction was then isolated by anion exchange chromatography (29).
The contents of each well were applied to a small anion exchange column (Bio-Rad AG-1-
X8) that had been pretreated with 15 ml of 0.1 M formic acid, 3 M ammonium formate,
followed by 15 ml of water. The columns were then washed with 10 ml of water followed
by 15 ml of a solution containing 5 mM sodium borate and 60 mM sodium formate.
[3H]Inositol phosphates were eluted with 4.5 ml of 0.1 M formic acid, 0.2 M ammonium
formate and quantitated by liquid scintillation spectrometry (LKB Wallace 1215 Rackbeta
scintillation counter).
Pharmacological parameters were analyzed using the KaleidaGraph program (Abelbeck
Software, version 3.01).
ELISA
For cell surface ELISA measurements, cells were transferred to 96-well dishes (4 –5 × 104
cells per well) 1 day after transfection. About 72 h after transfection, cells were fixed in 4%
formaldehyde in phosphate-buffered saline (PBS) for 30 min at room temperature. After
washing three times with PBS and blocking with DMEM (containing 10% FBS), cells were
incubated with the HA-specific monoclonal antibody (12CA5), 20 μg/ml, for 3 h at 37 °C.
Plates were washed and incubated with a 1:2000 dilution of a peroxidase-conjugated goat
anti-mouse IgG antibody (Sigma) for 1 h at 37 °C. Hydrogen peroxide and o-
phenylenediamine (each 2.5 mM in 0.1 M phosphate/citrate buffer, pH 5.0) served as
substrate and chromogen, respectively. The enzymatic reaction was stopped after 30 min at
room temperature with 1 M H2SO4 solution containing 0.05 M Na2SO3, and the color
development was measured bichromatically in the BioKinetics reader (EL312, BioTek
Instruments, Inc., Winooski, VT) at 490 and 630 nm (base line). The reading for cells
transfected with expression constructs coding for the human P2Y1 wild-type receptor was
approximately 0.5 OD units, and approximately 0.2 OD units for cells transfected with
vector DNA alone. The difference was normalized as 100% surface expression.
Western Blotting
Wild-type and all cysteine mutant receptors were detected with the polyhistidine monoclonal
antibody (0.5 μg/ml, clone BMG-His-1, Roche Molecular Biochemicals) directed against
the hexa-His tag present at the C-terminal domain of all receptors. Samples containing 50
μg of solubilized membrane protein prepared from transfected COS-7 cells as described
previously (30) were resolved by SDS-polyacrylamide gel electrophoresis (4 –20% miniplus
sepragel, Owl Separation Systems, Woburn, MA), electroblotted onto nitrocellulose, and
probed with the polyhistidine monoclonal antibody as described (31). Immunoreactive
proteins were detected by incubation with horseradish peroxidase-conjugated sheep anti-
mouse antibody (1:2500, Amersham Pharmacia Biotech) and visualized using an enhanced
chemiluminescence system (Amersham Pharmacia Biotech).
RESULTS
Cysteine Residues
Among P2Y receptors, four cysteines in the extracellular domains are conserved (21). For
the human P2Y1 receptor these cysteines are Cys42 in the N-terminal domain, Cys124 near
the exofacial end of TM3, Cys202 in EL2, and Cys296 in EL3. Each of these cysteine
residues was individually mutated to alanine, and the corresponding mutants were tested for
activation of PLC by three different agonists (2-MeSATP, 2-MeSADP, and HT-AMP). The
results are summarized in Table I. The C202A mutant receptor showed no activation up to
100 μM concentration of all agonists used in this study. Analogously, the C124A mutant
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receptor exhibited the same properties, with no increased stimulation of PLC detectable at
≤100 μM agonist.
All mutant receptors contained an HA epitope at the N terminus, allowing cell-surface
expression levels to be measured by ELISA (Table I). Both C124A and C202A mutant
receptors showed strongly diminished surface expression. The C124A mutant receptor was
detectable at approximately 10% of the level of the wild-type receptor, whereas the level of
the C202A mutant receptor was not significantly different from vector-transfected control.
Western blot analyses of membrane fractions prepared from transfected cells showed that
these cysteine mutant proteins were expressed in almost equal amounts compared with the
wild-type receptor (Fig. 1). These results, together with the lack of agonist-promoted
functional activity, suggest that a disulfide bridge between Cys124 and Cys202 is critical for
proper receptor trafficking of the human P2Y1 receptor to the cell surface. These results are
in concordance with previous studies indicating that this conserved disulfide bridge found in
the vast majority of GPCRs is important for proper receptor function (11, 32).
In contrast to the above cysteine mutant receptors, the C42A and C296A mutant receptors
were activated by 2-MeSADP; however, the 2-MeSADP concentration-response curves
were shifted by more than 1000-fold to the right compared with the wild-type receptor. The
same relative shift in receptor activation was observed for the two other agonist ligands
(Table I), indicating a similar influence on the general recognition of the agonist ligands.
The double point mutant C42A/C296A exhibited a similarly impaired response as the single
alanine mutants, indicating that the effect of this cysteine substitution is not additive (Fig. 2).
Although the expression levels of C42A, C296A, and C42A/C296A mutant receptors were
low, activation of PLC was clearly detectable. Control experiments (inositol phospate assay
and ELISA) in which the amount of DNA used for transfection was varied showed that the
wild-type P2Y1 receptor was significantly stimulated, even at expression rates as low as
10% of the normal expression level attained using 10 μg of DNA. No significant shift in
EC50 values was observed with a 10% expression rate of wild-type receptor (Fig. 3, A and
B); thus, the EC50 values observed for these three cysteine mutant receptors likely reflect the
intrinsic activity of these constructs.
Extracellular Loop 1
Only two positions in EL1 were selected for investigation of their influence on agonist
activation of P2Y1 receptors as follows: Cys124 (see above) and Lys125, which is
functionally conserved within the P2Y family. The K125A mutant showed no difference
compared with the wild-type receptor in agonist-promoted PLC activation. ELISA data for
this mutant receptor showed approximately 45% of wild-type receptor expression, indicating
that Lys125 does not influence receptor activation. No further mutations were made in EL1,
since this loop is presumed to be located distal to the ATP-binding site (6).
Extracellular Loop 2
Seven positively or negatively charged amino acids and one cysteine residue (see above) are
located in EL2. All of these amino acids were mutated individually to alanine. Although
R195A, K196A, K198A, D208A, and R212A mutant receptors showed no detectable
changes in activation of PLC and were well expressed on the cell surface (Table I), the
D204A and E209A mutant receptors behaved much differently. The D204A mutant receptor
was activated at 20 –25-fold higher agonist concentrations compared with the wild-type
receptor. Furthermore, this shift was observed for all agonists, independent of the length of
the 5′-phosphate chain. To investigate further the role of Asp204 in receptor activation, we
constructed D204E and D204N mutant receptors. Extension of the alkyl carboxylate side
Hoffmann et al. Page 5













chain at position 204 (D204E) further impaired agonist-promoted activation of the receptor,
resulting in a 55– 65-fold shift of the concentration-response curves. Surprisingly, the
relatively small change of a carboxylate to carboxamide in the D204N mutant receptor
caused an even greater change (200 –270-fold shift in EC50 values) in receptor activation
(Fig. 4 and Table I).
In contrast, the E209A mutant receptor exhibited a dramatically different activation pattern.
This mutant receptor was activated by >1000-fold higher concentrations of each agonist than
the wild-type receptor (Fig. 5 and Table I). The nature of the interaction of this carboxylate
side chain with agonists was further tested by additional mutant receptors E209D, E209Q,
and E209R. These mutant receptors were fully active and responded in a manner
indistinguishable from wild-type receptors (Table I).
Extracellular Loop 3
Beside Cys296 (see above), five charged amino acids were investigated in EL3. The R285A,
D289A, D300A, and R301A mutations had no effect on PLC activation, whereas the R287A
mutant receptor was activated at more than 1000-fold higher agonist concentrations than
wild-type receptors, and the profile of the concentration-response curves was surprisingly
similar to that of the E209A mutant receptor (see Fig. 5). Thus, Arg287 was targeted for a
more detailed analysis. The R287K, R287Q, and R287E mutant receptors were generated
and tested for PLC activation. The R287Q mutant receptor required >1,000-fold higher
agonist concentrations for activation of PLC compared with the wild-type receptor, whereas
the R287E mutant receptor was not significantly activated by agonist concentrations up to
100 μM. In contrast to these findings, receptor activity could be partially to fully retained by
changing Arg287 to lysine. However, the concentration-response curves for the nucleoside
diphosphate and triphosphate were shifted to the right (35- and 17-fold, respectively,
compared with wild-type receptors), whereas the concentration-response curve for the
nucleoside monophosphate was not shifted.
Since the E209A and R287A mutant receptors exhibited very similar activation patterns
when stimulated with 2-MeSADP (Fig. 5), we tested the hypothesis that a direct interaction
between these residues might be required for stabilization of the EL. Molecular modeling
studies of the EL (33) suggested that Glu209 and Arg287 might form an ionic interaction. The
double mutant E209R/R287E and the double deletion mutant E209A/R287A were
constructed and investigated. The double mutant E209R/R287E was not activated by agonist
concentrations up to 100 μM, indicating that the amino acids at these positions were not
interchangeable. The double mutant E209A/R287A exhibited an additive shift in
concentration-response curves for receptor activation (Fig. 5) compared with the single
mutants, suggesting that Glu209 and Arg287 affect receptor activation independently.
DISCUSSION
In the present study we have identified both charged residues and Cys residues within the
ELs of the human P2Y1 receptor that are critical for the activation of the receptor. We have
shown that the highly conserved disulfide bridge between the EL2 and TM3 is required for
proper functioning of the receptor. Since the double cysteine mutant receptor (C42A/C296A,
see Fig. 2) showed PLC activation similar to the single cysteine mutants (C42A and
C296A), we deduced the existence of an additional, critical disulfide bridge between the
EL3 and the N-terminal domain, which seems to be involved in receptor activation as well
as proper receptor trafficking to the cell surface. A similarly situated disulfide bridge was
found in the angiotensin AT1 receptor (26, 27), and it was concluded that this disulfide
bridge functions to position properly extracellular amino acids that are involved in the
binding of AT II. Sequence comparisons show that the angiotensin AT1 receptor is one of
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the most closely related receptor to the family of P2Y receptors (21). This novel disulfide
bridge would covalently constrain the helical bundle in a circular arrangement (33).
Moreover, each of the charged residues of EL2 and EL3 regions has been mutated, leading
to the observation that three of these residues (Asp204, Glu209, and Arg287) appear to be
involved in receptor activation and/or ligand recognition. Unfortunately, due to the lack of a
high affinity radioligand (34), we could not distinguish between effects on agonist binding
or on G protein coupling efficiency. At present the function of Asp204 remains to be
clarified, but this position appears to be very sensitive to even minor structural changes.
Glu209 was substituted by different amino acids, and all mutant receptors (except E209A)
were fully active and responded in a manner indistinguishable from wild-type receptors
(Table I). This indicates that this carboxylate group is more likely involved in hydrogen
bonding rather than an ionic interaction. The conformational requirements of this hydrogen
bonding would be largely flexible, since deletion of one methylene group (E209D mutant
receptor) or change of the charge (E209R mutant receptor) had no further influence on
receptor activation.
Arg287 was substituted by various amino acids. Removal (R287Q mutant) or change (R287E
mutant) of the charge of the amino acid side chain was not tolerated. Substitution of arginine
by lysine (R287K mutant) could partially to fully retain receptor activity, depending on the
length of the phosphate chain of the agonist used for receptor stimulation. Hence, Arg287
appears to participate in a direct ionic interaction with the phosphate group of an agonist,
which is crucial for receptor activation.
The possible existence of an ionic bridge between EL2 and EL3 via the side chains of
Glu209 and Arg287 could not be clarified by mutagenesis. Both residues might have a
combined function in maintaining the overall conformation of the receptor and/or through
direct interaction with the ligand, as indicated by the different response of the R287K mutant
receptor to different agonists (Table I). This issue is being explored in more detail through
molecular modeling and molecular dynamics simulations (33). An energetically sound
conformational hypothesis for the receptor has been calculated that includes transmembrane
(TM) domains (using the electron density map of rhodopsin as a template), extracellular
loops, and a truncated N-terminal region. ATP may be docked in the receptor, both within
the previously defined TM cleft and within two other regions of the receptor, termed meta-
binding sites, defined by the extracellular loops. The first meta-binding site is located
outside of the TM bundle, between EL2 and EL3, and the second meta-binding site is
positioned immediately underneath EL2 (33). In meta-binding site I, the side chain of Glu209
(EL2) is within hydrogen bonding distance (2.8 Å) of the ribose O-3′, and Arg287 (EL3)
coordinates both α- and β-phosphates of the triphosphate chain, consistent with the
insensitivity in potency of the 5′-monophosphate agonist, HT-AMP, to mutation of Arg287.
Additional experiments showed a selective reduction of potency for 3′-NH2-ATP in
activating the E209R mutant receptor (33). This is consistent with the hypothesis of direct
contact between Glu209 in EL2 and the nucleotide ligands, because the 3′-NH2 group is
positively charged and expected to have a repulsive interaction with the positively charged
arginine in the E209R mutant receptor.
Our data have identified two or three stable, steric constraints on the conformation of
otherwise highly flexible peptide loops suggesting a preferred three-dimensional
arrangement of these ELs (33). These constraints might be responsible for proper
positioning of amino acids involved in ligand recognition and/or receptor activation. Fig. 6
visually summarizes the currently available mutagenesis data for the human P2Y1 receptor,
obtained in the present and previous studies (5).
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Unlike the transmembrane domains in GPCRs, the length and amino acid composition of the
extracellular loops is highly variable. However, it is possible that the position rather than the
actual amino acid within the extracellular loops, especially the second loop, is important for
ligand recognition. For the human P2Y1 receptor, two amino acids, Asp204 and Glu209, were
identified as being critical for receptor activation. These amino acids are located two and
seven residues, respectively, beyond the Cys that forms the critical disulfide bridge between
EL2 and TM3 (Fig. 6 and 7). Previous studies have shown the involvement of EL2 of other
GPCRs in ligand recognition (Fig. 7). The amino acid in position Cys+22 was found to be
involved in ligand binding for the human Y1 neuropeptide Y receptor (35), the thyrotropin-
releasing hormone receptor of rat and mouse (14, 36), and subtype-specific agonist binding
in bombesin receptors (37) and cholecystokinin receptor types A and B (38). For the
substance P (NK-1) receptor from rat a six-amino acid portion of EL2, including the Cys+2
position, was found to be labeled by a photoreactive analogue of substance P (39). Almost
the same region of the human NK-1 receptor was found to be responsible for a loss of
agonist binding affinity, when substituted with the corresponding sequence of the human
NK-3 receptor (40). A study of chimeric adenosine A1/A3 receptors identified an 11-amino
acid portion of EL2, including the critical cysteine, to be responsible for subtype specificity
of ligand binding (13). Interestingly, in this chimeric receptor 8 amino acid residues were
altered, but the amino acid in position Cys+2 was conserved. In the human A2A receptor, a
glutamate residue three amino acids C-terminal to the cysteine in EL2 was found to be
involved in ligand binding (12). Interestingly, the position Cys+3 was not conserved in the
study of chimeric adenosine A1/A3 receptors (13). For the AT1 angiotensin receptor, the
position Cys+3 was also found to interact with the agonist (41). For the α1-adrenergic
receptor, three amino acids beyond the Cys were found to be responsible for a subtype-
specific antagonist binding profile (15).
Although there exist various examples in the literature for the importance of position Cys+2,
there are only a few reports that correlate with the importance of the glutamic acid at the Cys
+7 position. The only report showing the identical position to be important for ligand
recognition was found for the human Y1 neuropeptide Y receptor (35). Studies on thrombin
receptors have found a glutamic acid at the Cys+6 position to be important for agonist
specificity (42). The same group published a report on chimeric constructs of human and
Xenopus thrombin receptors, showing that an exchange of the C-terminal portion of the
EL2, including position Cys+7, results in a robust constitutive activity (43). Hence, it
appears that this portion of the EL2 might be important for maintaining the receptor in a
resting conformation. None of the positions that were found to be important in our study
were found to be important in the human interleukin-8 type A receptor (44). Nevertheless,
six amino acids in EL2 play an important role in agonist binding and/or subsequent Ca2+
mobilization.
The situation is different for EL3, because there is no conserved disulfide bridge in this loop
that could be used as a reference point for a sequence alignment. A smaller number of
studies reported amino acids in this loop to be important for proper receptor function. In
most cases the reported amino acids were located in vicinity to the TMs. In various GPCRs,
amino acids in the EL3 close to the top of TM6 (within 4 amino acids) are important for
receptor function or subtype specificity (30 –32, 35, 40, 45). This region would correspond
to Arg287, which we found to be important for receptor function.
In conclusion, our data so far are consistent with the presence of two critical disulfide
bridges and involvement of charged residues in ligand recognition. As suggested by
mutagenesis and molecular modeling, Glu209 and Arg287 serve bifunctional roles. In the
2The amino acids in positions Cys+2, Cys+3, and Cys+7 are located 2, 3, and 7 residues, respectively, beyond the cysteine.
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model Glu209 interacts with the 3′-OH group of the ribose moiety, whereas Arg287 interacts
with the α-phosphate of ATP (33). In the resting state of the receptor, these residues are
likely to form an ionic bridge between EL2 and TM6, thus acting as a gate for ligand entry
to the binding site within the helical bundle. The function of Asp204 still remains to be
clarified, but since the shift in concentration-response curves was consistent among mono-,
di-, or triphosphates, this result most likely excludes a direct involvement of this amino acid
in possible Mg2+ coordination.
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Fig. 1. Western blot analysis of receptor mutant expression
Wild-type and all cysteine mutant receptors were transiently expressed in COS-7 cells.
Samples containing 50 μg of solubilized membrane proteins prepared from whole
transfected COS-7 cells were applied to each lane and resolved by SDS-polyacrylamide gel
electrophoresis. Proteins were detected with a polyhistidine monoclonal antibody directed
against the hexa-His tag at the C-terminal domain of all receptors and a horseradish
peroxidase-conjugated sheep anti-mouse antibody. Lanes 1–7 correspond to control
(transfected with PCD-vector, lane 1), wild type (lane 2), C42A (lane 3), C124A (lane 4),
C202A (lane 5), C296A (lane 6), and C42A/C296A (lane 7) mutant receptors. Lanes 2–7
show an additional band at approximately 42 kDa, which is the size expected for the wild-
type P2Y1 and mutant receptors. All bands are of similar intensity, indicating equal
expression levels for wild-type and mutant receptors.
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Fig. 2. Concentration-response curves of P2Y1 receptors with mutated cysteine residues in the N-
terminal domain and the third extracellular loop
Wild-type human P2Y1 receptor (squares) or mutant receptors in which Cys42 (C42A,
circles) and/or Cys296 (C296A, diamond, and C42A/C296A, inverted triangle) were
converted to alanine and transiently expressed in COS-7 cells. [3H]Inositol phosphate
accumulation was measured following a 30-min incubation with increasing concentrations
of 2-MeSADP in the presence of 10 mM LiCl (see “Experimental Procedures” for details).
Maximal responses ranged from 2.5- to 4-fold increases in [3H]inositol phosphate
accumulation over basal. Concentration-response curves represent the mean values ± S.E. of
2 to 6 replicate experiments.
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Fig. 3. Stimulation of PLC in COS-7 cells transiently expressing wild-type human P2Y1
receptors (A, concentration-response curves; B, surface expression of receptor)
COS-7 cells were transfected with varied amounts of plasmid DNA coding for human P2Y1,
supplemented with the PCD-PS vector DNA to keep the amount of total DNA constant at 10
μg/dish. A, concentration-response curves for activation of PLC by stimulation with 2-
MeSADP. Transfections were done with the following amounts of P2Y1 plasmid DNA: 10
μg (squares), 1 μg (circles), 100 ng (triangle), 10 ng (inverted triangle), and none
(diamonds). B shows receptor surface expression of the same transfected cells as determined
by ELISA (see “Experimental Procedures” for details). Surface expression is presented as
percent expression relative to the expression observed in cell transfection with 10 μg of
plasmid coding for human P2Y1.
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Fig. 4. Concentration-response curves of P2Y1 receptors with mutated Asp
204 residues in the
second extracellular loop
Wild-type human P2Y1 receptor (squares) or mutant receptors in which Asp204 was mutated
to Ala (D204A, circles), Glu (D204E, diamond), or to Asn (D204N, triangle) were
transiently expressed in COS-7 cells. [3H]Inositol phosphate accumulation was measured
following a 30-min incubation with increasing concentrations of 2-MeSADP in the presence
of 10 mM LiCl (see “Experimental Procedures” for details). Maximal responses ranged from
2.5- to 4-fold increases in [3H]inositol phosphate accumulation over basal. Concentration-
response curves represent the mean values ± S.E. of 2 to 6 replicate experiments.
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Fig. 5. Concentration-response curves of P2Y1 receptors with mutated residues in the second
(Glu209) and third extracellular loop (Arg287)
Wild-type human P2Y1 receptor (squares) or mutant receptors in which Glu209 (E209A,
triangle) and/or Arg287 (R287A, diamond, and E209A/R287A, circle) were mutated to
alanine and transiently expressed in COS-7 cells. [3H]Inositol phosphate accumulation was
measured following a 30-min incubation with increasing concentrations of 2-MeSADP in
the presence of 10 mM LiCl (see “Experimental Procedures” for details). Maximal
responses ranged from 2.5- to 4-fold increases in [3H]inositol phosphate accumulation over
basal. Concentration-response curves represent the mean values ± S.E. of 2 to 6 replicate
experiments.
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Fig. 6. Hypothetical human P2Y1 receptor topology
All information is given for receptor stimulation upon application of 2-MeSADP. Shaded
amino acids exhibited 5-fold change in EC50 when mutated to alanine. Shaded and
underlined amino acids displayed a 5- to 20-fold shift when mutated to alanine or other
amino acids as indicated. Bold circled amino acids showed >20-fold shift when mutated to
alanine or other amino acids as indicated. The included data about residues in the
transmembrane domain were taken from Jiang et al. (5). Only one (Asn27) of 4 possible
glycosylation sites is indicated. The other possible glycosylation sites are Asn11, Asn113, and
Asn197.
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Fig. 7. Alignment of extracellular loop 2 amino acid sequences from various GPCRs
Residues in boldface were identified by point mutations and shown to be important for
receptor function, and underlined sequences were important for receptor function in
chimeric receptors (see “Discussion” for details). All sequences were aligned with respect to
the cysteine forming a disulfide bridge between EL2 and TM3. The numbers on the left
indicate the position of the starting amino acid in the receptor sequence.
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Table I
Receptor-stimulated PLC activation ([3H]inositol phosphate accumulation) and surface
expression assays (ELISA) of wild-type and mutant human P2Y1 receptors
EC50 values are mean values ± S.E. of two to seven independent experiments each done in duplicate. Maximal
stimulation for each receptor was between 2.5- and 4.5-fold over basal. Determination of surface expression





nM nM nM %
Wild-type 4.9 ± 3.3 2.2 ± 0.5 1,420 ± 580 100 ± 3
N-terminal domain
 C42A 21,200 ± 6,500 48,000 ± 500 >100,000 12 ± 4
Extracellular loop 1
 C124A NAa NA NA 10 ± 1
 K125A 12.9 ± 1.9 5.9 ± 7.8 6,600 ± 2,850 44 ± 3
Extracellular loop 2
 R195A 17.6 ± 14.6 4.7 ± 0.6 2,100 ± 680 218 ± 3
 K196A 4.0 ± 0.6 2.5 ± 0.8 2,660 ± 540 175 ± 4
 K198A 5.0 ± 2.8 17.5 ± 2.1 2,720 ± 1,350 241 ± 3
 C202A NA NA NA 0 ± 7
 D204A 119 ± 17 66.5 ± 11.5 22,800 ± 3,200 183 ± 5
 D204N 1,000 ± 70 595 ± 5.0 >100,000 29 ± 2
 D204E 267 ± 3.4 145 ± 15.4 24,400 ± 5,700 81 ± 2
 D208A 27.0 ± 11.6 3.6 ± 0.7 1,990 ± 720 109 ± 4
 E209A 17,000 ± 8,500 17,200 ± 7,400 >100,000 28 ± 3
 E209D 3.1 ± 0.2 3.2 ± 0.6 9,310 ± 5,200 127 ± 8
 E209Q 5.1 ± 1.5 8.6 ± 2.1 6,410 ± 1,880 135 ± 13
 E209R 2.7 ± 0.2 4.9 ± 1.3 4,180 ± 320 77 ± 3
 R212A 3.9 ± 2.9 7.8 ± 5.5 1,810 ± 780 93 ± 3
Extracellular loop 3
 R285A 33.2 ± 24.5 9.2 ± 5.4 2,440 ± 1,530 129 ± 3
 R287A 52,100 ± 35,100 14,800 ± 2,600 >100,000 161 ± 4
 R287K 80.9 ± 3.1 74.9 ± 5.5 4,210 ± 610 193 ± 1
 R287Q 9,670 ± 5,310 5,290 ± 360 >100,000 77 ± 1
 R287E >100,000 >100,000 >100,000 76 ± 2
 D289A 10.5 ± 7.1 3.9 ± 0.4 3,940 ± 280 79 ± 13
 C296A 19,600 ± 5,700 5,160 ± 920 >100,000 20 ± 5
 D300A 25.7 ± 12.2 9.8 ± 0.5 10,900 ± 770 124 ± 3
 R301A 9.0 ± 7.3 2.6 ± 0.3 3,480 ± 690 111 ± 4
Double mutants
 E209R/R287E >100,000 >100,000 >100,000 117 ± 4
 E209A/R287A >100,000 >100,000 >100,000 77 ± 3


















nM nM nM %
 C42A/C296A 2,250 ± 160 3,420 ± 1,380 >100,000 8 ± 5
a
NA, no activation detectable for ≤100 μM agonist.
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